A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This trial is a single-center, Phase 1, placebo-controlled, double-blind, multiple-dose study
in two ascending dose cohorts of healthy subjects. The primary objective of the trial is to
assess the safety and tolerability of multiple doses of MN-08 tablet administered for 6.5
consecutive days in healthy subjects.